Category

• Pipeline3

Organizations

• Bausch + Lomb64
• Eyes On Eyecare42
• Alcon, Inc.41
• American Optometric Association34
• Harrow26
• Glaukos25
• Regeneron21
• Aldeyra Therapeutics20
• Sight Sciences19
• American Academy Of Ophthalmology18

Tags

• Dry Eye Disease3
• Clinical Trials2
• Eye Drops2
• Dry Eye1
• Eye Drop Solution1
• Glaucoma1
• Licensing Agreement1

• Organizations: Stuart Therapeutics ✕

Clear all

Pipeline

Stuart Therapeutics reports initial phase 3 DED eye drop data

Results on ST-100 (vezocolmitide), a collagen mimetic peptide, support its role as a fast-acting resolution for dry eye signs and symptoms.

Pipeline

Stuart Therapeutics initiates phase 3 DED trial for vezocolmitide

Topical formulation aims to improve tear production, symptom relief, and reduce ocular surface damage.

Pipeline

Glaukos acquires global rights to Stuart Therapeutics' neuroprotection glaucoma asset

Proprietary therapeutic has been shown to function independently of IOP control.